HCAT Health Catalyst, Inc.

What a time it’s been for Health Catalyst. In the past six months alone, the company’s stock price has increased by a massive 48.7%, reaching $1.76 per share. This performance may have investors wondering how to approach the situation.

Software is eating the world, and virtually no business is left untouched by it. The undeniable tailwinds fueling the industry have also led to strong returns for SaaS stocks lately as they’ve gained 47.2% over the past six months, outpacing the S&P 500’s 21.4% rise.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Health Catalyst is back in focus after analysts revised fair value from about US$2.10 to roughly US$1.83 per share, which points to a more cautious stance on the stock. Recent research has shifted from earlier optimism with price targets in the US$2 to US$3 range to current levels closer to US$1.80, as analysts weigh execution risks around churn, divestitures and the durability of growth in its health technology offerings. In this article, you will see how these changing targets fit into the...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

The data analytics company has cycled through three CEOs in eight months. Health Catalyst is betting its newest chief can navigate an AI pivot and revenue headwinds.

A number of stocks fell in the afternoon session after Bloomberg reported that Anthropic’s preliminary second-quarter revenue topped $11.5 billion.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Health Catalyst’s second quarter was marked by a notable decline in sales, which management attributed primarily to the ongoing impact of client migrations and a reduction in lower-margin services. The company’s decision to divest Vitalware, its revenue cycle management business, was described by CEO Ben Albert as necessary to focus on areas of highest conviction, despite the near-term revenue impact. Albert acknowledged the structural challenges facing health systems and emphasized that the div

Company divests Vitalware for $147M, retires $160M debt amid platform migration.

Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 12.7% year on year to $70.49 million. On the other hand, next quarter’s revenue guidance of $55.5 million was less impressive, coming in 10.7% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.

Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 23.1% in the afternoon session after the company provided a weak third-quarter revenue forecast and lowered its full-year outlook, despite topping second-quarter revenue expectations.

Moby summary of Health Catalyst, Inc.'s Q2 2026 earnings call

Health Catalyst (NASDAQ:HCAT) reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook, while outlining a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses. Chief Executive Officer Ben

Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Health Catalyst (HCAT) delivered earnings and revenue surprises of +100.00% and +2.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.7% year on year to $70.49 million. On the other hand, next quarter’s revenue guidance of $55.5 million was less impressive, coming in 10.7% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.

A number of stocks jumped in the afternoon session after the software sector caught a massive tailwind, fueled by easing geopolitical tensions and a fresh wave of AI-driven M&A.

A number of stocks fell in the afternoon session after sentiment continued to weaken as tech stocks faced a dual headwind of deteriorating macro conditions and an unwinding of retail leverage.

Health Catalyst (NASDAQ:HCAT) stockholders approved three of four proposals presented at the company’s 2026 annual meeting, including the election of two directors, ratification of the company’s auditor and an advisory vote on executive compensation. A proposal to phase out the company’s classified

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Health Catalyst has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $2.26. The stock also fell short of the S&P 500’s 8.2% gain during that period.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.